Gabapentin Capsule
Product Images NDC 80425-0196

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 80425-0196). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description (Description)

Chemical structure of gabapentin, showing a cyclohexane ring with two side groups: an amino methyl group (CH2NH2) and a carboxymethyl group (CH2CO2H).*

FDA Label Image

Label 3 (Label 3)

Gabapentin 300 mg capsule label from Advanced Rx Pharmacy of Tennessee, LLC. The package compares the product to Neurontin and includes storage instructions, lot number, expiration date (11/1/2023), and NDC 80425-0196. The label shows a green and yellow color scheme with text specifying it is a 300 mg capsule.*

FDA Label Image

Label 1 (Lable 1)

Gabapentin 300 mg capsule packaging label from Advanced Rx Pharmacy of Tennessee, LLC, Nashville, Tennessee. The label includes storage instructions, a barcode, lot number 30GAB3001123, expiration date 11/1/2023, and comparison to Neurontin with reference NDC 69367-0344-05. The label also shows the manufacturer as Westminster PHA.*

FDA Label Image

Label 2 (Lable 2)

Gabapentin 300 mg capsule label from Advanced Rx Pharmacy of Tennessee, LLC. The label shows a quantity of 60 capsules, with comparison to Neurontin. The label includes storage instructions and a lot number with an expiration date of 11/1/2023. Barcodes and manufacturing details for Westminster Pharma are visible.*

FDA Label Image

Fig 1 (Fig 1)

A line graph comparing mean pain scores over an 8-week period between placebo and Gabapentin 3,600 mg/day groups. The x-axis shows weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, indicating a decrease for Gabapentin versus stable scores for placebo.*

FDA Label Image

Fig 2 (Fig 2)

A line graph depicting mean pain score over a 7-week period, comparing placebo with Gabapentin at dosages of 1,800 mg/day and 2,400 mg/day. The x-axis represents weeks from baseline to week 7, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Fig 3 (Fig 3)

A bar graph comparing the percentage response rates between placebo (PBO) and gabapentin (GBP) at different dosages across two studies. Study 1 shows response rates for PBO and GBP 3,600 mg, while Study 2 shows PBO, GBP 1,800 mg, and GBP 2,400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Fig 4 (Fig 4)

A scatter plot chart showing the percentage difference on the vertical axis against daily doses of 600 mg, 900 mg, 1200 mg, and 1800 mg on the horizontal axis. Data points are labeled for three different studies: Study a (black squares), Study b (dark gray squares), and Study c (light gray squares), indicating varying percentage differences at each dose level.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.